3 Evidence

3 Evidence

The appraisal committee (sectionĀ 7) considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group. In response to consultation, the company submitted additional clinical evidence and cost-effectiveness analyses that focused on the population whose condition had been treated with first-line tyrosine kinase inhibitor therapy. See the committee papers for full details of the evidence.

  • National Institute for Health and Care Excellence (NICE)